Line 1: |
Line 1: |
| + | Welcome! |
| + | |
| + | |
| + | We are creating content for all diseases with genetic findings in the current WHO Classification of Tumours books. Please join the effort! |
| + | |
| + | |
| + | To volunteer: |
| + | |
| + | #Select a link in the table to your book(s) of interest to view specific authorship opportunities. Additional books are in the process of being added. |
| + | #'''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]''' with your disease page of interest. You will be connected with an Associate Editor to help guide you through the process. |
| + | #Complete the brief '''[https://mms.cancergenomics.org/members/form.php?orgcode=CGC&fid=3830649 <u>Volunteer Form</u>]''' to receive your log-in credentials. Information on [[Description of CCGA Roles|<u>Authorship and Other Roles</u>]] with the CCGA is available. |
| + | |
| | | |
| {| class="wikitable" | | {| class="wikitable" |
| + | |+BOOKS WITH CONTENT IN PROGRESS |
| + | !Book Name |
| + | !Book Edition |
| + | !Book Acronym |
| |- | | |- |
− | |'''Disease'''||'''Page Type'''||'''Author'''||'''Associate Editor''' | + | |[[HAEM5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues]] |
− | !Author Content (Pending or Complete)
| + | |5th |
− | !Editor Reviewed (Date)
| + | |HAEM5 |
| |- | | |- |
− | |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''|| ||Fabiola Quintero-Rivera (FQR) | + | |[[CNS5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of the Central Nervous System]] |
− | | | + | |5th |
− | | | + | |CNS5 |
| |- | | |- |
− | | Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive||Disease | + | |[[GTS5:Volunteer Assignments and Opportunities|WHO Classification of Genetic Tumour Syndromes]] |
− | | ||FQR
| + | |5th |
− | | | + | |GTS5 |
− | | | |
| |- | | |- |
− | | Chronic Neutrophilic Leukemia (CNL)||Disease | + | |[[BRST5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of the Breast]] |
− | | ||FQR
| + | |5th |
− | | | + | |BRST5 |
− | | | |
| |- | | |- |
− | | Polycythaemia Vera (PV)||Disease | + | |[[STBT5:Volunteer Assignments and Opportunities|WHO Classification of Soft Tissue and Bone Tumours]] |
− | | ||FQR
| + | |5th |
− | | | + | |STBT5 |
− | | | |
| |- | | |- |
− | | Primary Myelofibrosis (PMF)||Disease | + | |[[DIG5:Volunteer Assignments and Opportunities|WHO Classification of Digestive System Tumours]] |
− | | ||FQR
| + | |5th |
− | |
| + | |DIG5 |
− | |
| + | |} |
− | |-
| + | |
− | | Essential Thrombocythaemia (ET)||Disease
| + | |
− | | ||FQR
| + | {| class="wikitable" |
− | |
| + | |+BOOKS COMING SOON |
− | |
| + | !Book Name |
− | |-
| + | !Book Edition |
− | | Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease
| + | !Book Acronym |
− | | ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease
| |
− | | ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Mastocytosis'''''||'''''Overview'''''|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Cutaneous Mastocytosis||Disease
| |
− | | ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Systemic Mastocytosis||Disease
| |
− | | ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Mast Cell Sarcoma||Disease
| |
− | | ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)'''''||'''''Overview'''''|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Chronic Myelomonocytic Leukemia (CMML)||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Juvenile Myelomonocytic Leukemia (JMML)||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myelodysplastic Syndrome (MDS) with Excess Blasts||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myelodysplastic Syndrome (MDS) with Isolated del(5q)||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myelodysplastic Syndrome (MDS), Unclassifiable||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Refractory Cytopenia of Childhood||Disease|| ||FQR
| |
− | |
| |
− | |
| |
− | |-
| |
− | | || || ||
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''|| ||Jennelle Hodge (JH)
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Myeloid Neoplasms with Germline Predisposition'''''||'''''Overview'''''|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukaemia with Germline CEBPA Mutation||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloid Neoplasms with Germline DDX41 Mutation||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloid Neoplasms with Germline RUNX1 Mutation||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloid Neoplasms with Germline ANKRD26 Mutation||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloid Neoplasms with Germline ETV6 Mutation||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloid Neoplasms with Germline GATA2 Mutation||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities'''''||'''''Overview'''''|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Promyelocytic Leukemia (APL) with PML-RARA||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) with Mutated NPM1||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) with Mutated RUNX1||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Therapy-Related Myeloid Neoplasms||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | |''Acute Myeloid Leukemia (AML), Not Otherwise Specified''||'''''Overview'''''|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) with Minimal Differentiation||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) without Maturation||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myeloid Leukemia (AML) with Maturation||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Myelomonocytic Leukemia||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Monoblastic and Monocytic Leukemia||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Pure Erythroid Leukemia||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Megakaryoblastic Leukemia (AMKL)||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Basophilic Leukemia||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Panmyelosis with Myelofibrosis||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Myeloid Sarcoma||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Myeloid Proliferations Associated with Down Syndrome'''''||'''''Overview'''''|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Myeloid Leukemia Associated with Down Syndrome||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Blastic Plasmacytoid Dendritic Cell Neoplasm||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Acute Leukemias of Ambiguous Lineage'''''||'''''Overview'''''|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Acute Undifferentiated Leukemia||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | ??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | ??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease|| ||JH
| |
− | |
| |
− | |
| |
− | |-
| |
− | | || || ||
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''|| ||Yassmine Akkari (YA)
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Early T-Cell Precursor Lymphoblastic Leukemia||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | |NK-Lymphoblastic Leukemia/Lymphoma||Disease|| ||YA
| |
− | |
| |
− | |
| |
− | |-
| |
− | | || || ||
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| ||Snehal Patel (SP)
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Monoclonal B-cell Lymphocytosis||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |B-cell Prolymphocytic Leukemia||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Splenic Marginal Zone Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Hairy Cell Leukemia||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Splenic Diffuse Red Pulp Small B-cell Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Hairy Cell Leukemia Variant||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Lymphoplasmacytic Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Waldenstrom Macroglobulinemia||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Heavy Chain Diseases'''''||'''''Overview'''''|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Mu Heavy Chain Disease||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Gamma Heavy Chain Disease||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Alpha Heavy Chain Disease||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Plasma Cell Neoplasms||'''''Overview'''''|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Non-IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Plasma Cell Myeloma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Plasma Cell Myeloma Variants||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Plasmacytoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Primary Amyloidosis||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Light Chain and Heavy Chain Deposition Disease||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | POEMS Syndrome||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | TEMPI Syndrome||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease|| ||SP | |
− | |
| |
− | |
| |
− | |-
| |
− | |Nodal Marginal Zone Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Paediatric Nodal Marginal Zone Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Follicular Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Testicular Follicular Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | In Situ Follicular Neoplasia||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Duodenal-Type Follicular Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Paediatric-Type Follicular Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Large B-cell Lymphoma with IRF4 Rearrangement||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Primary Cutaneous Follicle Centre Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Mantle Cell Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | Leukemic Non-Nodal Mantle Cell Lymphoma||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | In Situ Mantle Cell Neoplasia||Disease|| ||SP
| |
− | |
| |
− | |
| |
− | |-
| |
− | | || || ||
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Greg Corboy (GC)
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||GC
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | | | |
− | | | |
− | |- | |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example | |
− | | | |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
− | |-
| |
− | |Example||Example|| ||Example
| |
− | |
| |
− | |
| |
| |- | | |- |
− | |Example||Example|| ||Example | + | |[[EYE5:Volunteer Assignments and Opportunities|WHO Classification of Eye and Orbit Tumours]] |
− | | | + | |5th |
− | | | + | |EYE5 |
| |- | | |- |
− | |Example||Example|| ||Example | + | |[[SKIN5:Volunteer Assignments and Opportunities|WHO Classification of Skin Tumours]] |
− | | | + | |5th |
− | | | + | |SKIN5 |
| |- | | |- |
− | |Example||Example|| ||Example | + | |[[HAN5:Volunteer Assignments and Opportunities|WHO Classification of Head and Neck Tumours]] |
− | | | + | |5th |
− | | | + | |HAN5 |
| |- | | |- |
− | |Example||Example|| ||Example | + | |[[ENDO5:Volunteer Assignments and Opportunities|WHO Classification of Endocrine and Neuroendocrine Tumours]] |
− | | | + | |5th |
− | | | + | |ENDO5 |
| |- | | |- |
− | |Example||Example|| ||Example | + | |[[MALE5:Volunteer Assignments and Opportunities|WHO Classification of Urinary and Male Genital Tumours]] |
− | | | + | |5th |
− | | | + | |MALE5 |
| |- | | |- |
− | |Example||Example|| ||Example | + | |[[PEDS5:Volunteer Assignments and Opportunities|WHO Classification of Paediatric Tumours]] |
− | | | + | |5th |
− | | | + | |PEDS5 |
| |- | | |- |
− | |Example||Example|| ||Example | + | |[[THOR5:Volunteer Assignments and Opportunities|WHO Classification of Thoracic Tumours]] |
− | | | + | |5th |
− | | | + | |THOR5 |
| |- | | |- |
− | |Example||Example|| ||Example | + | |[[FEMA5:Volunteer Assignments and Opportunities|WHO Classification of Female Genital Tumours]] |
− | | | + | |5th |
− | | | + | |FEMA5 |
| |} | | |} |